Email this article 
Post a Comment Experience of determination of antitumor drugs concentrations as a method of providing the safety of pharmacotherapy
- Authors: Rodionov G.G.1, Shantyr’ I.I.1, Ushal I.E.1, Kolobova E.A.1, Svetkina E.V.1, Oseshnyuk R.A.2, Shabanov P.D.2
-
Affiliations:
- Nikiforov Russian Center of Emergency and Radiation Medicine, EMERCOM of Russia
- Institute of Experimental Medicine
- Issue: Vol 16, No 1 (2018)
- Pages: 64-70
- Section: Articles
- URL: https://journals.rcsi.science/RCF/article/view/8782
- DOI: https://doi.org/10.17816/RCF16164-70
- ID: 8782
Cite item
Full Text
Abstract
Abstract. Background. The undesirable side effects in the process of pharmacotherapy are forced to look for ways to prevent them. The most effective means for this is to carry out individual therapeutic drug monitoring. This is especially true for patients who undergo chemotherapy. A narrow therapeutic range of antineoplastic agent concentrations requires an individual approach to the management of each patient.
The purpose of this study is to justify the need for therapeutic drug monitoring to provide the safety of antitumor drugs.
Methods. Methods for the quantitative determination of the active metabolite of fludarabine, imatinib and gefitinib in human blood plasma have been developed and validated. A study of pharmacokinetics of antitumor drugs: fludarabine — 36 patients, gefitinib — 24 healthy volunteers, imatinib — 24 healthy volunteers.
Results and Discussion. The work shows the magnitude of interindividual differences of the pharmacokinetics of various antitumor drugs. High interindividual variability of pharmacokinetic parameters was revealed both in patients and in healthy volunteers.
Conclusion. Experience of the Research Laboratory of Toxicology and Drug Monitoring, The Nikiforov Russian Center of Emergency and Radiation Medicine, EMERCOM of Russia on the application of therapeutic drug monitoring showed its relevance and effectiveness for patients undergoing chemotherapy.
Full Text
##article.viewOnOriginalSite##About the authors
Gennadii G. Rodionov
Nikiforov Russian Center of Emergency and Radiation Medicine, EMERCOM of Russia
Author for correspondence.
Email: rodgengeor@yandex.ru
Dr. Med. Sci., Associate Prof., Head of the Research Laboratory of Toxicology and Drug Monitoring
Russian Federation, Saint PetersburgIgor I. Shantyr’
Nikiforov Russian Center of Emergency and Radiation Medicine, EMERCOM of Russia
Email: rodgengeor@yandex.ru
Dr. Med. Sci., Professor, Head of Bioindication division
Russian Federation, Saint PetersburgInna E. Ushal
Nikiforov Russian Center of Emergency and Radiation Medicine, EMERCOM of Russia
Email: innaushal@mail.ru
PhD Chem. Sci., Research Associated of the Research Laboratory of Toxicology and Drug Monitoring
Saint PetersburgEkaterina A. Kolobova
Nikiforov Russian Center of Emergency and Radiation Medicine, EMERCOM of Russia
Email: ekatderyabina@mail.ru
PhD Chem. Sci., Research Associated of the Research Laboratory of Toxicology and Drug Monitoring
Russian Federation, Saint PetersburgEkaterina V. Svetkina
Nikiforov Russian Center of Emergency and Radiation Medicine, EMERCOM of Russia
Email: moerabo4eemilo@gmail.com
Research Associated of the Research Laboratory of Toxicology and Drug Monitoring
Russian Federation, Saint PetersburgRodion A. Oseshnyuk
Institute of Experimental Medicine
Email: rao81@mail.ru
Fellow, S.V. Anichkov Dept. of Neuropharmacology
Saint PetersburgPetr D. Shabanov
Institute of Experimental Medicine
Email: pdshabanov@mail.ru
Dr. Med. Sci., Professor, Head, S.V. Anichkov Dept. of Neuropharmacology
Russian Federation, Saint PetersburgReferences
- Кукес В.Г. Метаболизм лекарственных средств: клинико-фармакологические аспекты. – М.: Реафарм, 2004. [Kukes VG. Metabolism of medicines: clinical and pharmacological aspects. Moscow: Reafarm; 2004. (In Russ.)]
- Общероссийская общественная организация трансплантологов «Российское трансплантологическое общество». Лекарственный мониторинг и взаимозаменяемость оригинальных и генерических иммунодепрессантов с узким терапевтическим индексом. Национальные клинические рекомендации. – 2014. Доступ по ссылке http://www.minzdravrb.ru/minzdrav/docs/lmi_2013.pdf. [All-Russian public organization of transplantologists “Russian transplant society”. Drug monitoring and the relationship of original and generic immunosuppressants with a narrow therapeutic index. National Clinical Recommendations. 2014. Available from: http://www.minzdravrb.ru/minzdrav/docs/lmi_2013.pdf. (In Russ.)]
- Лепахин В.К., Астахова А.В., Овчинникова Е.А., Овчинникова Л.К. Врачебные ошибки как причина осложнений лекарственной терапии // Качественная клиническая практика. – 2002. – № 1. – С. 71–77. [Lepakhin VK, Astakhova AV, Ovchinnikova EA, Ovchinnikova LK. Medical errors as a cause of complications of drug therapy. Kachestvennaya klinicheskaya praktika. 2002;(1):71-77. (In Russ.)]
- Осешнюк Р.А., Ушал И.Э., Светкина Е.В., и др. Межиндивидуальные особенности фармакокинетики противоопухолевых препаратов у здоровых добровольцев // Обзоры по клинической фармакологии и лекарственной терапии. – 2017. – Т. 15. – № 1. – С. 48–52. [Oseshnyuk RA, Ushal IE, Svetkina EV, et al. Individual peculiarities in pharmacokinetics of antiblastomic drugs in healthy volunteers. Reviews on clinical pharmacology and drug therapy. 2017;15(1):48-52. (In Russ.)]
- Приказ министерства здравоохранения Российской Федерации № 64 от 21 февраля 2000 г. «Об утверждении номенклатуры клинических лабораторных исследований». [Order of the Ministry of Health of the Russian Federation No 64 of 21 Feb 2000. “On the approval of the nomenclature of clinical laboratory research”. (In Russ.)]
- Сычев Д.А., Раменская Г.И., Игнатьев Г.В. Клиническая фармакогенетика / Под ред. В.Г. Кукеса, Н.П. Бочкова. – М.: ГЭОТАР-Медиа, 2007. [Sychev DA, Ramen skaya GI, Ignat’ev GV. VG Kukes, NP Bochkov, editors. Clinical pharmacogenetics. Moscow: GEOTAR-Media; 2007. (In Russ.)]
- Davies A, Hayes AK, Knight K, et al. Simultaneous determination of nilotinib, imatinib and its main metabolite (CGP-74588) in human plasma by ultra-violet high performance liquid chromatography. Leuk Res. 2010; 34(6):702-707. doi: 10.1016/j.leukres.2009.11.009.
- Ernst FR, Grizzle AJ. Drug-related morbidity and mortality: updating the cost-of-illness model. J Am Pharm Assoc (Wash). 2001;41(2):192-199. doi: 10.1016/S0003-0465(15)33027-5.
- Bhatia AL, Csillag A, Mitchison DA, et al. The virulence in the guinea-pig of tubercle bacilli isolated before treatment from South Indian patients with pulmonary tuberculosis. 2. Comparison with virulence of tubercle bacilli from British patients. Bull World Health Organ. 1961;25:313-322.
- Guengerich FP. Cytochromes P450, drugs, and diseases. Mol Interv. 2003;3(4):194-204. doi: 10.1124/mi.3.4.194.
- Johnson JA, Bootman JL. Drug-related morbidity and mortality. A cost-of-illness model. Arch Intern Med. 1995;155(18):1949-1956.
- Jha N, Bajracharya O, Namgyal T. Prevalence of adverse drug reactions with commonly prescribed drugs in different hospitals of Kathmandu valley. Kathmandu Univ Med J (KUMJ). 2007;5(4):504-510.
- Kalow W, Gunn DR. Some statistical data on atypical cholinesterase of human serum. Ann Hum Genet. 1959;23:239-250. doi: 10.1111/j.1469-1809.1959.tb01467.x.
- Lokhov PG, Maslov DL, Trifonova OP, et al. Mass spectrometry analysis of blood low-molecular fraction as a method for unification of therapeutic drug monitoring. Biochemistry (Moscow) Supplement Series B: Biomedical Chemistry. 2014;8(1):1-10. doi: 10.1134/s1990750814010119.
- World Health Organization. Medicines: rational use of medicines. Geneva; 2010.
- Samani NJ, Tomaszewski M, Schunkert H. The personal genome – the future of personalised medicine? Lancet. 2010;375(9725):1497-1498. doi: 10.1016/S0140-6736(10)60598-3.
- Veeraraghavan S, Thappali S, Viswanadha S, et al. Simultaneous quantification of ruxolitinib and nilotinib in rat plasma by LC-MS/MS: application to a pharmacokinetic study. J Pharm Biomed Anal. 2014;94:125-131. doi: 10.1016/j.jpba.2014.01.040.
